Physician profile
Marshall James
NPI 1134179963
$3,576.53
in general payments reported to CMS, 2019-2025
22 companies · $1,088 in 2025
The $1,088 reported for 2025 was more than what 87% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $192 · 2020: $79.52 · 2021: $244 · 2022: $197 · 2023: $711 · 2024: $1,066 · 2025: $1,088.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,864.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,864.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $525.79 | 2023-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Abbvie INC. | $411.43 | 2021-2024 | |
| Neurocrine Biosciences, INC. | $375.76 | 2023-2025 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $367.29 | 2020-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Axsome Therapeutics, INC. | $316.45 | 2024-2025 | Auvelity |
| Alkermes, INC. | $242.86 | 2019-2025 | Lybalvi, Aristada |
| Indivior INC. | $201.69 | 2021-2025 | Sublocade, Perseris |
| Vanda Pharmaceuticals INC. | $171.52 | 2022-2025 | Fanapt |
| Exact Sciences Corporation | $158.27 | 2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Novo Nordisk INC | $134.89 | 2019-2021 | |
| Noven Therapeutics, LLC | $107.35 | 2022-2025 | Secuado, Xelstrym |
| Abbott Laboratories | $107.32 | 2023 | Freestyle Libre 3 |
| Glaxosmithkline, LLC. | $99.06 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $88.74 | 2025 | Cobenfy |
| Lundbeck LLC | $82.20 | 2023-2024 | Rexulti |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $42.66 | 2021-2025 | Invega Sustenna |
| Hikma Pharmaceuticals USA | $35.26 | 2022 | |
| Rhodes Pharmaceuticals L.P. | $28.64 | 2019 | |
| Novartis Pharmaceuticals Corporation | $26.39 | 2019-2021 | |
| Orexo US, INC. | $20.35 | 2025 | Zubsolv |
| Avanir Pharmaceuticals, INC. | $16.56 | 2019 | |
| Baxter Healthcare | $16.05 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marshall James listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.